CAJ | 학술논문

肝静脉闭塞病(HVOD)是造血干细胞移植(HSCT)后的严重并发症之一,重度HVOD患者的死亡率可高达100％.去纤苷是一种具有抗血栓及促进纤溶作用的单链寡核苷酸混合物.近年来,多个临床研究结果说明去纤苷是预防和治疗HSCT后HVOD安全有效的药物.文章就去纤苷的作用机制及其在HSCT后HVOD的治疗及预防中的应用进行总结.
간정맥폐새병(HVOD)시조혈간세포이식(HSCT)후적엄중병발증지일,중도HVOD환자적사망솔가고체100％.거섬감시일충구유항혈전급촉진섬용작용적단련과핵감산혼합물.근년래,다개림상연구결과설명거섬감시예방화치료HSCT후HVOD안전유효적약물.문장취거섬감적작용궤제급기재HSCT후HVOD적치료급예방중적응용진행총결.
Hepatic veno-occlusive disease (HVOD) is a serious complication of hematopoietic stem cell transplantation.The mortality rate of severe HVOD (sHVOD) approaches 100 ％.Defibrotide (DF) is a polydisperse mixture of single-stranded oligonucleotides with antithrombotic and fibrinolytic properties.Numerous clinical trials have demonstrated its effectiveness and safety in the prevention and treatment of HVOD.This review focuses on the possible mechanisms of action of DF and its use in the prevention and treatment of HVOD.